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Abstract
Background: Obesity is associated with increased cardiovascular diseases and diabetes mellitus.
Guidelines call for intensified glucose and lipid screening among overweight and obese patients.
Data on compliance with these guidelines are scarce. The purpose of this study was to assess rates
of diabetes and lipid screening in primary care according to demographic variables and weight
status.
Methods:  Over a 3-year follow-up period, we assessed screening rates for blood glucose,
triglycerides, and HDL- and LDL-cholesterol among 5025 patients in primary care. From
proportional hazards models we estimated screening rates among low, moderate, high, and very-
high risk patients and compared them with recommendations of the American Diabetes
Association (ADA), National Cholesterol Education Program (ATP III) and U.S. Preventive Services
Task Force (USPSTF).
Results: Mean (SD) age was 47.4 (15.6); 69% were female, 21% were non-white, and 30% of males
and 25% of females were obese (BMI ≥ 30 kg/m2). For both diabetes and lipid screening, the
adjusted hazard was 260–330% higher among ≥65 than <35 year-olds, 50–90% higher in persons
with BMI ≥ 35 than <25 kg/m2, 10–30% lower for females than males, and not lower among racial/
ethnic minorities. Screening rates were at least 80% among very-high risk persons, which we
defined as 55–64 years old, BMI ≥ 35 kg/m2, non-white, with baseline hypertension. In contrast,
high-risk persons who were younger (35–44 years old) and less obese (BMI 30–<35 kg/m2) were
screened less often (43% for LDL-cholesterol among females to 83% for diabetes among males)
even though ADA, ATP III and USPSTF recommend diabetes and lipid screening among them.
Conclusion: Patients with higher BMI or age were more likely to be screened for cardiometabolic
risk factors. Women were screened at lower rates than men. Even in a highly structured medical
group practice, some obese patients were under-screened for diabetes and dyslipidemia.
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Background
An estimated 97 million adults in the United States are
overweight or obese [1]. The presence of overweight and
obesity substantially increases the risk of morbidity from
several diseases, particularly cardiovascular diseases and
diabetes mellitus [2,3].
Clinical guidelines call for intensified diabetes and lipid
screening among overweight and obese v. non-overweight
persons [4-7] (Table 1). Despite these recommendations
few data exist on compliance with them.
During the years 1998 to 2000, Ealovega et al [8] assessed
3-year diabetes screening rates among 8286 non-diabetic
patients, aged ≥45 years, who were members of a health
management organization in Michigan. Overall 69% were
screened. In multivariate logistic regression analysis, only
history of hypertension (OR 3.96 [95% CI 2.53, 6.19])
and history of dyslipidemia (3.96 [2.53, 6.19]) were inde-
pendent predictors of screening. However, reported prev-
alence of overweight or obesity in this study was less than
10%, and thus the results may not be generalizable to
other populations.
Kern et al [9] assessed 3-year diabetes screening rates
among 301 non-diabetic patients at an academic general
internal medicine practice in New York City. Overall 78%
were screened. In multivariate logistic regression analysis,
age (OR 12.36 [95% CI 3.41, 44.79] for ≥45 v. <45 years),
sex (0.45 [0.21, 0.93] for female v. male), ethnicity (3.71
[1.68, 8.20] for non-white v. white), family history of dia-
betes (2.98 [1.12, 7.93]), BMI (1.08 [1.00, 1.18] per unit,
kg/m2), and number of visits (1.33 [1.12, 1.58] per visit)
were independent predictors of screening. However, these
results may not be generalizable to non-academic health
care settings, the sample size was small, and the authors
did not assess screening rates according to body mass
index (BMI) level.
In the 2001 Behavioral Risk Factor Surveillance System
(BRFSS), 72.5% of participants reported having their
blood cholesterol checked in the past 5 years [10]. Unad-
justed predictors of cholesterol screening included sex
(74.7% among females v. 70.5% among males), race/eth-
nicity (75.3% among white non-Hispanics v. 64.2%
among Hispanics) and age (43.1% for persons 18–24
years to 90.4% for persons age 65–74 years). However, the
BRFSS relied on self-reports, which can result in over- or
under-estimates of prevalence of screening compared with
health care records. Also, that study did not assess screen-
ing rates by BMI category or control for confounding var-
iables.
Table 1: Guidelines for diabetes mellitus and lipid screening.
Diabetes mellitus screening
Recommendations of the American Diabetes Association (ADA) [4]
Testing should be considered for those ≥45 years of age and repeated every 3 years, if results are normal.
Testing should be considered younger or more frequently for those who:
(i) are African-, Hispanic-, Native-, Asian-, or Pacific Island-American
(ii) are overweight (BMI, kg/m2 ≥ 25);
(iii) have had gestational diabetes or delivered a baby weighing >9 pounds;
(iv) have a positive family history of diabetes (parents or siblings);
(v) have hypertension (blood pressure ≥ 140/90 mmHg);
(vi) have low HDL cholesterol (≤ 35 mg/dl) and/or high triglyceride level (≥ 250 mg/dl);
(vii) have had impaired glucose (110 ≤ fasting plasma glucose < 126 mg/dl or 140 ≤ oral glucose tolerance test < 200 mg/dl).
Recommendations of the U.S. Preventive Services Task Force (USPSTF) [5]
The USPSTF recommends screening for type 2 diabetes in adults with hypertension or hyperlipidemia.
Lipid screening
Recommendations of the National Cholesterol Education Program (ATP III) [6]
In adults ≥20 years of age, a fasting lipoprotein profile (total cholesterol, LDL and HDL cholesterol) is recommended every 5 years. More frequent 
measurements are recommended for persons with multiple risk factors or, in those with 0–1 risk factor, if the LDL level is only slightly below the 
goal level. If the testing opportunity is non-fasting, only the values for total and HDL cholesterol will be usable. In such a case, if total cholesterol 
≥200 mg/dL or HDL < 40 mg/dL, a follow-up lipoprotein profile is needed for appropriate management based on LDL.
Recommendations of the U.S. Preventive Services Task Force (USPSTF) [7]
The USPSTF recommends that clinicians screen men aged ≥35 years and women aged ≥45 years and younger adults (men 20–35 and women 20–45 
years) if they have other risk factors for coronary heart disease (diabetes, a family history of cardiovascular disease before age 50 years in male 
relatives or age 60 years in female relatives, a family history suggestive of familial hyper-lipidemia, multiple coronary heart disease risk factors [e.g. 
tobacco use, hypertension]). The USPSTF recommends that screening for lipid disorders include measurement of total cholesterol and HDL-
cholesterol measured on non-fasting or fasting samples. The optimal interval for screening is uncertain. On the basis of other guidelines and expert 
opinion, reasonable options include every 5 years, shorter intervals for people who have lipid levels close to warranting therapy, and longer 
intervals for low-risk people who have had low or repeatedly normal lipid levels.BMC Health Services Research 2008, 8:25 http://www.biomedcentral.com/1472-6963/8/25
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The objective of this study was to examine diabetes and
lipid screening rates according to demographic variables
and BMI categories in a setting where screening rates are
likely to be relatively high.
Methods
Participants
The patients for this study were a subset of participants in
the HMO Research Network's Center for Education and
Research on Therapeutics Patient Safety Cohort Study
[11]. Eligibility criteria for this analysis included being a
member of both Harvard Pilgrim Health Care (insurance
plan) and a multi-site, multi-specialty group practice
(Harvard Vanguard Medical Associates), being continu-
ously enrolled throughout 1999, and having a BMI meas-
urement between January 1, 2000 and December 31,
2000.
Using electronic medical records, we identified 13,846
patients who were members of Harvard Pilgrim Health
Care and Harvard Vanguard Medical Associates and who
had a visit in 2000. Of 13,846 we excluded 6451 patients
who did not a BMI measurement between January 1, 2000
to December 31, 2000. Of 7395 patients who met eligibil-
ity criteria for this analysis, we excluded 1467 whose
membership ended before June 30, 2001 (not enough
time to assess follow-up screening) and 536 who had an
ICD-9 diagnosis of one of the following medical condi-
tions related to weight loss before June 30, 2001 (to assure
the index BMI was not altered by pre-existing illness):
AIDS, cancer, malabsorption syndrome, or alcohol use
disorder, and 367 who had a cardiovascular event before
the index date (congestive heart failure, unstable angina,
myocardial infarction, coronary artery bypass grafting,
percutaneous coronary intervention, coronary artery dis-
ease, ischemic stroke, visceral arterial disease, or periph-
eral arterial disease). These exclusions left a cohort for
analysis of 5025 patients.
Comparison of the 5025 participants in this analysis with
5716 of the 10,741 not included in this analysis showed a
higher proportion of females (69% v. 56%), lower pro-
portion of white race (79% v. 83%), slightly lower mean
age (46.6 v. 47.6 years) and BMI (27.2 v. 27.5 kg/m2), but
did not vary by proportion of patients with baseline
hypertension (24% v. 25%) or diabetes (10% v. 10%).
We excluded 662 participants with diabetes mellitus or
impaired glucose tolerance at baseline from blood glucose
screening analysis. We excluded 1057 participants with
hypertriglyceridemia, low HDL-cholesterol, or high LDL-
cholesterol at baseline from lipid screening analysis. We
defined the index date as BMI measurement closest to
December 31, 2000 but not before January 1, 2000. This
approach provided up to a 2-year window, January 1,
1999 to December 31, 2000, to assess baseline diabetes
and lipid abnormalities. We defined follow-up as 30 days
before index date through 3 years after index date. (see
Figure 1)
All procedures were in accordance with the ethical stand-
ards for human subjects established by the Declaration of
Study timeline, showing inception (1/1/99), range of index dates (1/1/00 to 12/31/00), and follow-up time period (30 days  before index date to 3 years after index date) Figure 1
Study timeline, showing inception (1/1/99), range of index dates (1/1/00 to 12/31/00), and follow-up time period (30 days 
before index date to 3 years after index date).BMC Health Services Research 2008, 8:25 http://www.biomedcentral.com/1472-6963/8/25
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Helsinki. The institutional review board of Harvard Pil-
grim Health Care approved the study protocols. Informed
consent of individual patients was not necessary as this
was a study of deidentified data.
Measurements
From electronic medical records, we obtained height and
weight, sex, race/ethnicity, and date of birth to calculate
age at index date. We included a missing category for race/
ethnicity because values were missing on 35% of patients.
We also assessed baseline cardiovascular risk factors,
including hypertension, diabetes mellitus, hypertriglycer-
idemia, low HDL-cholesterol, and high LDL-cholesterol,
between January 1, 1999 to index date. (see Additional
file 1)
We obtained laboratory data to assess the outcome meas-
ures, which were screening tests done during the follow-
up period for blood glucose (random or fasting), triglyc-
erides (fasting), and HDL-cholesterol (random or fasting)
and LDL-cholesterol (fasting).
Statistical Analysis
We assessed 3-year screening proportions by categories of
BMI, age, sex, race/ethnicity, and baseline hypertension
and (except for blood glucose screening) diabetes mellitus
status. Next we assessed time-to-screening by multivariate
proportional hazards models. We right-censored partici-
pants when membership in the health plan ended, at first
date of diagnosis of medical condition causing weight loss
(AIDS, cancer, malabsorption syndrome, or alcohol use
disorder), or at first date of a cardiovascular event (conges-
tive heart failure, unstable angina, myocardial infarction,
coronary artery bypass grafting, percutaneous coronary
intervention, coronary artery disease, ischemic stroke, vis-
ceral arterial disease, or peripheral arterial disease),
whichever came first. Our primary model included BMI
category, age category, sex and race/ethnicity. In subse-
quent models, we added baseline hypertension and dia-
betes mellitus as covariates.
Using parameter estimates from our multivariate models,
we estimated predicted 3-year screening proportions
among selected patients who were at low, moderate, high,
and very-high risk for coronary heart disease and diabetes
that we defined by levels of age, BMI, race/ethnicity, and
baseline hypertension status, separately for males and
females. For each combination of risk factors, we indicate
whether published guidelines recommend screening for
diabetes or dyslipidemia [4-7]. In this paper we show pre-
dicted screening proportions for 12 of the possible 160
combinations of risk factors, which we selected to show a
wide variety of the possible combinations.
Using baseline characteristics, we also segregated patients
in the cohort into two categories: those who should have
been screened and those who did not need to be screened
based on USPSTF guidelines [6,7]. Then, among those
who should have been screened, we assessed 3-year
screening rates and evaluated determinants of under-
screening using multivariate proportional hazards mod-
els.
Results
Among 5025 patients, mean (SD, range) age was 47.4
(15.6, 17.1 – 97.7) years; 3484 (69%) were female and
1541 (31%) were male. At baseline, 24%, 46%, 20%, and
10% of males and 46%, 29%, 14%, and 10% of females
had a BMI of <25, 25–<30, 30–<35, and ≥35 kg/m2,
respectively. Table 2 shows that increasing BMI category
was associated with higher rates of baseline cardiovascular
risk factors. For example, 18% of males in the lowest BMI
category had baseline hypertension and rates rose monot-
onically to 48% in the highest BMI category. Baseline dia-
betes rates increased from 7% to 32%,
hypertriglyceridemia rates increased from 6% to 20%, and
low HDL cholesterol increased from 7% to 24% among
males from lowest to highest BMI category. Men and
women had different absolute rates of baseline cardiovas-
cular risk factors, but similar increases across BMI catego-
ries.
A total of 66% of patients had a glucose screening test
(10% fasting and 90% random). Table 3 shows that com-
pared with patients with BMI < 25 kg/m2, the adjusted
hazard ratios (HR) for glucose screening were 1.2, 1.4, and
1.5 for patients with BMI 25–<30, 30–<35, and ≥35 kg/
m2, respectively. Females were somewhat less likely to be
screened than males (HR 0.9, [95% CI 0.8, 1.0]). Hispanic
patients were more likely to be screened than whites (1.5
[1.1, 2.0]). Patients with higher age were more likely to be
screened: HR 3.6 [3.1, 4.1] for patients ≥65 compared
with patients <35 years). In a second model, further
adjusted for baseline hypertension, we found that base-
line hypertension was only a modest independent predic-
tor of glucose screening (1.1 [1.0, 1.2]).
Overall, 41% of patients were screened for triglyceride
level. As with glucose screening, triglyceride screening rose
substantially across categories of BMI and age. (Table 3)
Females were substantially less likely to be screened than
males (0.7, [0.6, 0.8]). In two additional models, further
adjusted for baseline diabetes and hypertension, we
found that diabetes was a strong independent predictor of
triglyceride screening (1.5 [1.2, 1.8]) whereas hyperten-
sion predicted only a modest increase in screening rates
(1.1 [1.0, 1.2]).BMC Health Services Research 2008, 8:25 http://www.biomedcentral.com/1472-6963/8/25
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The overall proportion screened of LDL-cholesterol
(40%) was similar to that of triglyceride screening, but
HDL-cholesterol showed a higher overall rate (57%). For
both HDL- and LDL-cholesterol, as with triglyceride
screening, higher BMI and age predicted higher screening
rates, and female sex predicted lower rates. Likewise, base-
line diabetes and hypertension predicted higher HDL-
cholesterol screening rates to an extent similar to that of
triglyceride screening. (Table 3)
Table 4 shows predicted 3-year screening proportions
among low, moderate, high, and very-high risk patients,
by sex, and contrasted these rates with the ADA, ATP III,
and USPSTF recommendations [4-7]. For both diabetes
and lipid screening, clinicians screened at least 80% of
very-high risk persons, which we defined as 55–64 years
old, BMI ≥ 35 kg/m2, non-white, with baseline hyperten-
sion. In contrast, clinicians screened persons that we
deemed high risk somewhat less frequently than recom-
mended. For example, ADA, ATP III, and USPSTF recom-
mend both diabetes and lipid screening among patients
35–44 years old, BMI 30–<35 kg/m2, non-white, with
baseline hypertension, but clinicians screened only 43%
(LDL-cholesterol for females) to 83% (diabetes for males)
of these patients. As expected, screening rates for low- and
moderate-risk patients were lower still.
In a secondary analysis, we examined determinants of
screening only among those for whom guidelines recom-
mend screening. Based on USPSTF guidelines, 27% and
53% of patients should have been screened for diabetes
and lipid disorders, respectively [5,7]. Among those who
should have been screened for diabetes, 83% were
screened. Among those who should have been screened
for lipid disorders, the screening rate for LDL-cholesterol
(55%) was similar to that of triglycerides (56%), but
HDL-cholesterol showed a higher screening rate (71%).
For both diabetes and lipid screening, increasing BMI was
associated with higher rates of screening. Patients whose
BMI was ≥ 35 were 41% more likely to be screened for dia-
betes than those whose BMI was <25 (HR 1.4, [95% CI
1.1, 1.7]); analogous hazard ratios for the other outcomes
were 1.7 (1.4, 2.1) for triglycerides, 1.6 (1.3, 1.9) for HDL-
cholesterol, and 1.7 (1.4, 2.0) for LDL-cholesterol. Older
age was also associated with higher screening rates, with
hazard ratios for those ≥ 65 years old ranging from 1.9 to
2.5 compared to those <35 years old. Women were
screened at lower rates than men for lipid disorders (haz-
Table 2: Baseline characteristics by BMI category and sex (N = 1541 males and N = 3484 females)
BMI (kg/m2)
Males Females
<25 25–<30 30–<35 ≥35 <25 25–<30 30–<35 ≥35
(n = 374) (n = 705) (n = 315) (n = 147) (n = 1618) (n = 1010) (n = 500) (n = 356)
% of Subjects
Age, years
< 3 5 2 61 51 01 1 3 4 2 4 2 02 2
3 5 – 4 4 2 12 12 22 7 2 7 2 3 2 32 4
4 5 – 5 4 2 62 73 13 3 1 9 2 2 2 02 9
5 5 – 6 4 1 21 61 61 4 7 1 1 1 51 4
≥65 15 21 20 16 12 20 23 12
Race/ethnicity
Black 4 4 6 10 4 8 11 13
H i s p a n i c 1122 1 2 21
O t h e r 1 0 521 8 6 41
W h i t e 3 85 25 34 3 5 6 5 3 5 25 0
Missing 48 39 38 44 31 31 31 35
Hypertension 18 30 44 48 10 24 34 38
Diabetes 7 12 22 32 3 6 18 22
Hypertriglyceridemia 6 17 23 20 3 11 19 18
Low HDL 7 17 20 24 4 14 24 22
High LDL 8 17 17 16 4 11 18 13B
M
C
 
H
e
a
l
t
h
 
S
e
r
v
i
c
e
s
 
R
e
s
e
a
r
c
h
 
2
0
0
8
,
 
8
:
2
5
h
t
t
p
:
/
/
w
w
w
.
b
i
o
m
e
d
c
e
n
t
r
a
l
.
c
o
m
/
1
4
7
2
-
6
9
6
3
/
8
/
2
5
P
a
g
e
 
6
 
o
f
 
9
(
p
a
g
e
 
n
u
m
b
e
r
 
n
o
t
 
f
o
r
 
c
i
t
a
t
i
o
n
 
p
u
r
p
o
s
e
s
)
Table 3: Proportion screened and adjusted hazard ratios of blood glucose and lipid screening
Glucose (N = 4363) Triglyceride (N = 3968) HDL-C (N = 3968) LDL-C (N = 3968)
N Proportion 
Screened (%)
Adjusted HR 
(95% CI)
N Proportion 
Screened (%)
Adjusted HR 
(95% CI)
Proportion 
Screened (%)
Adjusted HR 
(95% CI)
Proportion 
Screened (%)
Adjusted HR 
(95% CI)
Model 1.
Age (years)
<35 1197 41% 1.0 (ref) 1150 19% 1.0 (ref) 34% 1.0 (ref) 18% 1.0 (ref)
35–44 1123 61% 1.6 (1.5, 1.8) 1067 36% 1.9 (1.6, 2.2) 53% 1.6 (1.4, 1.9) 34% 1.9 (1.6, 2.3)
45–54 1007 79% 2.7 (2.4, 3.0) 895 52% 3.0 (2.5, 3.5) 69% 2.5 (2.2, 2.8) 52% 3.1 (2.7, 3.7)
55–64 458 83% 3.0 (2.6, 3.4) 374 66% 4.1 (3.4, 4.9) 80% 3.3 (2.9, 3.9) 65% 4.3 (3.6, 5.2)
≥65 578 90% 3.6 (3.1, 4.1) 482 62% 4.1 (3.4, 4.9) 78% 3.3 (2.8, 3.8) 62% 4.3 (3.6, 5.2)
BMI (kg/m2)
<25 1887 57% 1.0 (ref) 1799 32% 1.0 (ref) 49% 1.0 (ref) 31% 1.0 (ref)
25–<30 1485 70% 1.2 (1.1, 1.3) 1292 45% 1.3 (1.1, 1.4) 60% 1.1 (1.0, 1.2) 44% 1.3 (1.1, 1.4)
30–<35 632 76% 1.4 (1.2, 1.5) 538 51% 1.5 (1.3, 1.7) 65% 1.3 (1.1, 1.5) 49% 1.4 (1.2, 1.7)
≥35 359 75% 1.5 (1.4, 1.8) 339 57% 1.9 (1.6, 2.3) 68% 1.6 (1.4, 1.9) 55% 1.9 (1.6, 2.2)
Sex
Male 1254 73% 1.0 (ref) 1120 54% 1.0 (ref) 67% 1.0 (ref) 52% 1.0 (ref)
Female 3109 63% 0.9 (0.8, 1.0) 2848 36% 0.7 (0.6, 0.8) 52% 0.8 (0.7, 0.8) 35% 0.7 (0.6, 0.8)
Race/ethnicity
White 2288 65% 1.0 (ref) 2059 41% 1.0 (ref) 58% 1.0 (ref) 40% 1.0 (ref)
Black 267 64% 1.1 (0.9, 1.3) 256 37% 1.0 (0.8, 1.3) 54% 1.0 (0.9, 1.2) 36% 1.0 (0.8, 1.3)
Hispanic 67 70% 1.5 (1.1, 2.0) 64 31% 1.0 (0.7, 1.6) 52% 1.2 (0.8, 1.7) 30% 1.0 (0.6, 1.6)
Other 257 67% 1.3 (1.1, 1.6) 237 38% 1.1 (0.9, 1.3) 55% 1.0 (0.9, 1.3) 41% 1.1 (0.9, 1.3)
Missing 1484 66% 1.1 (1.0, 1.2) 1352 41% 1.1 (1.0, 1.2) 56% 1.0 (0.9, 1.1) 37% 1.1 (1.0, 1.2)
Model 2. Model 1 + Diabetes
Diabetes
No -- -- -- 3787 39% 1.0 (ref) 55% 1.0 (ref) 38% 1.0 (ref)
Yes -- -- -- 181 72% 1.5 (1.2, 1.8) 80% 1.3 (1.1, 1.6) 71% 1.4 (1.2, 1.7)
Model 3. Model 1 + Hypertension
Hypertension
No 3555 61% 1.0 (ref) 3285 36% 1.0 (ref) 53% 1.0 (ref) 35% 1.0 (ref)
Yes 808 85% 1.1 (1.0, 1.2) 683 61% 1.1 (1.0, 1.2) 76% 1.1 (1.0, 1.3) 60% 1.1 (0.9, 1.2)
CI = confidence intervalBMC Health Services Research 2008, 8:25 http://www.biomedcentral.com/1472-6963/8/25
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ard ratios 0.8), but sex was not associated with diabetes
screening rates (HR 1.1, [95% CI 0.95, 1.2]).
Discussion
For both diabetes and lipid screening, we found that
screening rates increased with BMI and age and were
lower among females than males. We did not find that
screening rates were lower among racial/ethnic minori-
ties. The same patterns held whether we examined deter-
minants of screening among cohort as a whole or among
the subset for whom the USPSTF recommends screening.
Despite the fact that higher BMI, older age, and presence
of hypertension (and diabetes) predicted appropriately
higher screening rates, some absolute rates lagged behind
recommendations. For diabetes and lipid screening, clini-
cians adequately screened very-high risk patients (at least
80% across screening tests). However, patients who were
younger (35–44 years old) and less obese (BMI 30–<35
kg/m2), but still high enough risk to meet screening guide-
lines, were screened less often, 43% to 83% depending on
the test and patient sex. Screening rates for the moderate-
risk patients were lower still, however the evidence for
screening is weaker. (Table 4)
We found that females were screened less than males
across all risk factor levels. While females are at lower risk
than males for developing CHD, screening guidelines do
not differ by sex, except that male sex counts as a risk fac-
tor in determining optimal LDL-cholesterol level [6].
Also, USPSTF recommends lipid screening for males, but
not females, who were in our moderate risk categories of
35–44 years old, BMI 25–<30 kg/m2, white, without base-
line hypertension [7]. One possible explanation for
underscreening among females is that women obtain
some of their primary care from non-internal medicine
providers, such as gynocologists, who may not routinely
screen patients for diabetes and dyslipidemia. Other pos-
sible explanations are provider bias or failure to control
for confounding factors such as education status or
income level. Unfortunately, we did not have data to
address these hypotheses.
Racial/ethnic minorities were not screened less than
whites. In fact Hispanic persons had higher rates of glu-
cose screening, which appears appropriate given that His-
panic Americans have higher prevalence of diabetes than
whites [12].
We found that screening rates for triglyceride (41%) and
LDL-cholesterol (40%) were lower than for glucose (66%)
and HDL-cholesterol (57%). One possible explanation
for lower triglyceride and LDL-cholesterol screening rates
is that these tests require fasting blood samples for accu-
rate measurement, whereas HDL-cholesterol and glucose
do not. Another possible explanation is that clinicians
were following USPSTF guidelines, which do not recom-
mend for or against triglyceride measurement as part of
routine screening for lipid disorders.
This study had several strengths. The sample size was rel-
atively large, included males and females, and had some
Table 4: Predicted 3-year screening proportions among selected low, moderate, high, and very-high risk patients, by sex, and whether 
published guidelines recommend screening for diabetes and dyslipidemia.
Risk level Age 
(years)
BMI 
(kg/m2)
Race/
ethnicity
HTN Sex Glucose Triglyceride HDL-C LDL-C Screening recommended
ADA ATP III USPSTF
DM Lipid DM Lipid
Low <35 <25 White No F 41% 18% 36% 17% No No No No
M 44% 25% 44% 23%
Moderate <35 <25 Non-white No F 48% 19% 38% 18% Yes No No No
M 52% 25% 46% 24%
35–44 25–<30 White No F 63% 37% 56% 36% Yes Yes No No
M 67% 49% 66% 47% Yes
High 35–44 30–<35 Non-white Yes F 79% 46% 67% 43% Yes Yes Yes Yes
M 83% 58% 76% 55%
45–54 ≥35 White Yes F 90% 70% 85% 68% Yes Yes Yes Yes
M 92% 82% 92% 80%
Very high 55–64 ≥35 Non-white Yes F 95% 81% 93% 80% Yes Yes Yes Yes
M 97% 91% 97% 89%
BMI = body mass index. HTN = hypertension during the baseline time period. HDL-C = HDL-cholesterol. LDL-C = LDL-cholesterol. ADA = 
American Diabetes Association. ATP III = National Cholesterol Education Program. USPSTF = U.S. Preventive Services Task Force. DM = diabetes 
mellitus.BMC Health Services Research 2008, 8:25 http://www.biomedcentral.com/1472-6963/8/25
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racial/ethnic diversity. In addition, the medical group
practice employed fully electronic medical records
throughout the study period, which we used in our analy-
sis for physician diagnoses, procedures, medication use,
laboratory results, and blood pressure and BMI measure-
ments. Because patients included in our analysis were
continuously enrolled in both an insurance plan and a
medical group and had a BMI measurement, our results
may not generalize to other populations.
Limitations of this study include lack of data on socioeco-
nomic status. In addition, race/ethnicity was missing on
34% of patients. However, in a comparison of race data
from the electronic medical records to member self-
reports, it was found that blacks were only slightly more
likely to be counted as missing (38% of blacks vs. 32% of
whites) relative to whites (unpublished data, Adams AS).
Therefore, we do not think that missing race is a bias. We
were also missing data on two risk factors that ATP III rec-
ommends to assign LDL-cholesterol risk category, namely
cigarette smoking and family history of premature coro-
nary heart disease. The LDL-cholesterol goal for persons
with multiple (at least two of five) risk factors is <130 mg/
dL. We may have incorrectly used the goal <160 mg/dL
instead of 130 for patients who smoked or had a family
history of premature CHD, which would have reduce the
number of patients excluded for high LDL-cholesterol at
baseline. The lack of data on two of five risk factors could
have biased screening rates in either direction. For exam-
ple, we would expect a patient with an abnormal LDL
level at baseline to get follow-up tests more often, which
would falsely increase screening rates. On the other hand,
a clinician may be waiting longer than the 3-year follow-
up period to re-screen a patient with a normal baseline
screening result, which would have falsely decreased
screening rates. We did not examine blood concentrations
of the risk factors, or evaluate the extent to which physi-
cians appropriately treated, managed, and controlled
patient risk factor levels after an abnormal screening
result. Therefore, we could not assess the direction of LDL-
cholesterol screening bias.
We could not estimate over-screening of low risk patients
because we lacked information on risk factors that the
guidelines prescribed. Also, while our follow-up period
was 3 years, national guidelines recommend diabetes
screening every three years and lipid screening every five
years for low risk persons [4-7].
Although we excluded participants with diabetes mellitus
or impaired glucose tolerance at baseline from blood glu-
cose screening analysis, we could not completely distin-
guish between diabetes screening and diabetes case
finding. For example, a patient with new onset polyuria
but undiagnosed diabetes would be included in our glu-
cose screening analysis.
Conclusion
In summary, while patients with higher BMIs were more
likely to be screened for both diabetes and dyslipidemia,
a substantial portion of overweight and obese patients
were not screened to the extent that national guidelines
recommend. In addition, females appeared to be under-
screened for these cardiometabolic risk factors. Future
research should compare health outcomes among
screened and unscreened individuals, and examine more
detailed determinants of screening practices in medical
care. Health plans and clinical groups could develop inter-
ventions to improve screening rates.
Competing interests
None declared for JPF. SRS, KL, and MWG received grant
support from Sanofi-Aventis. HC is employed as Director
of Epidemiology in the US Medical Affairs Department of
Sanofi-Aventis.
Authors' contributions
SLR refined the study design, performed the statistical
analysis and drafted the manuscript. JPF, KL, HC, and
MWG conceived the study. MWG obtained funding. All
authors made substantial contributions to design of the
overall study, interpretation of data, and writing of the
paper. All authors read and approved the final manu-
script.
Additional material
Acknowledgements
This study was supported by Sanofi-Aventis.
References
1. Kuczmarski RJ, Carroll MD, Flegal KM, Troiano RP: Varying body
mass index cutoff points to describe overweight prevalence
among U.S. adults: NHANES III (1988 to 1994).  Obes Res
1997, 5(6):542-8.
2. Ford ES, Williamson DF, Lie S: Weight change and diabetes inci-
dence: findings from a national cohort of US adults.  Am J Epi-
demiol 146(3):214-22. 1997 Aug 1;
3. Lipton RB, Liao Y, Cao G, Cooper RS, McGee D: Determinants of
incident non-insulin-dependent diabetes mellitus among
blacks and whites in a national sample. The NHANES I Epi-
Additional file 1
Definitions of baseline cardiovascular risk factors. The file includes defi-
nitions of baseline cardiovascular risk factors, including hypertension, dia-
betes mellitus, hypertriglyceridemia, low HDL-cholesterol, and high LDL-
cholesterol.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1472-
6963-8-25-S1.doc]Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Health Services Research 2008, 8:25 http://www.biomedcentral.com/1472-6963/8/25
Page 9 of 9
(page number not for citation purposes)
demiologic Follow-up Study.  Am J Epidemiol 138(10):826-39.
1993 Nov 15; Erratum in: Am J Epidemiol 1994 May 1;139(9):964.
4. The Expert Committee on the Diagnosis and Classification
of Diabetes Mellitus.  Diabetes Care 2002, 25:S5-S20.
5. Screening for Type 2 Diabetes Mellitus in Adults: Recom-
mendations and Rationale. U.S. Preventive Services Task
Force (USPSTF)   [http://www.ahrq.gov/clinic/3rduspstf/diabscr/
diabetrr.htm]
6. Third Report of the National Cholesterol Education Panel
(NCEP) Expert Panel on Detection, Evaluation, and Treat-
ment of High Blood Cholesterol in Adults (Adult Treatment
Panel or ATP III).  NIH Publication No. 01-3305 2001.
7. Screening for Lipid Disorders: Recommendations and
Rationale  Article originally in Am J Prev Med 2001, 20(3S73-76 [http:/
/www.ahrq.gov/clinic/ajpmsuppl/lipidrr.htm]. Agency for Healthcare
Research and Quality, Rockville, MD
8. Ealovega MW, Tabaei BP, Brandle M, Burke R, Herman WH: Oppor-
tunistic screening for diabetes in routine clinical practice.
Diabetes Care 2004, 27(1):9-12.
9. Kern LM, Callahan MA, Brillon DJ, Vargas M, Mushlin AI: Glucose
testing and insufficient follow-up of abnormal results: a
cohort study.  BMC Health Serv Res 6:87. 2006 Jul 12;
10. Ahluwalia IB, Mack KA, Murphy W, Mokdad AH, Bales VS: State-
specific prevalence of selected chronic disease-related char-
acteristics – Behavioral Risk Factor Surveillance System,
2001.  MMWR Surveill Summ 2003, 52:1-80.
11. Chan for the HMO Research Network CERT Safety Investigators:
Advances in patient safety: from research to implementation. Concepts and
methodology Volume 2. Edited by: Henriksen K, Battles JB, Marks ES,
Lewin DI. AHRQ Publication No. 05-0021-2. Rockville, MD: AHRQ;
2005:225-38. 
12. National Institute of Diabetes and Digestive and Kidney Dis-
eases. National Diabetes Statistics fact sheet: general infor-
mation and national estimates on diabetes in the United
States, 2005  2005 [http://diabetes.niddk.nih.gov/dm/pubs/statistics/
index.htm#10]. Bethesda, MD: U.S. Department of Health and
Human Services, National Institute of Health
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1472-6963/8/25/prepub